| Action: User Message | Details: Hey | |
| Action: Response | Details: Hi there. I'm glad you're back. We were discussing your investment preferences and profile. I'd like to introduce you to a potential stock that might align with your interests. The company is Eli Lilly and Company, a well-established player in the healthcare industry. They specialize in developing and marketing human pharmaceuticals worldwide. What would you like to know more about Eli Lilly and Company? | |
| Action: User Message | Details: Hey | |
| Action: Response | Details: Hi there. I'm glad you're back. We were discussing your investment preferences and profile. I'd like to introduce you to a potential stock that might align with your interests. The company is Eli Lilly and Company, a well-established player in the healthcare industry. They specialize in developing and marketing human pharmaceuticals worldwide. What would you like to know more about this company? | |
| Action: User Message | Details: Hey | |
| Action: Response | Details: Good morning. Welcome back to our conversation. I'm excited to explore a potential new stock idea with you. Today, we're going to examine Eli Lilly and Company. Eli Lilly is a well-established company in the healthcare industry, known for its wide range of pharmaceutical products, including treatments for diabetes, cancer, and other diseases. Before we dive in, what would you like to know more about Eli Lilly and its financial performance? | |
| Action: User Message | Details: Do you think Elilily is a good fit for me? | |
| Action: Response | Details: Based on our previous conversations, you mentioned a preference for growth stocks and cyclical stocks. Eli Lilly does fit into the healthcare sector, but what specifically about the company's growth prospects and recent performance aligns well with your interest in growing your investment? Would you like me to summarize the company's recent financial metrics mentioned in its Q2 2023 earnings call? | |
| Action: User Message | Details: please | |
| Action: Response | Details: In Q2 2023, Eli Lilly reported a 28% revenue growth, driven by strong sales of several of its products, particularly Mounjaro. The company also raised its revenue guidance for 2023, expecting a range of $33.4 billion to $33.9 billion. Additionally, its operating income increased by 69%. How do you think this growth story aligns with your investment strategy, focusing on cyclical stocks with the potential for high returns? | |
| Action: User Message | Details: pretty good | |
| Action: Response | Details: With 28% revenue growth, that's a significant increase. What's your impression of the company's guidance for 2023, and do you think it's realistic or conservative? | |
| Action: User Message | Details: I do not know | |
| Action: Response | Details: The updated guidance suggests a relatively strong outlook for the company. Let me break it down further. Eli Lilly increased its revenue guidance by $2.2 billion, with a net price increase of 2% in the U.S. driven by Mounjaro. The company also expects gross margin to reach approximately 80% in 2023, driven by sales of rights for Baqsimi and its olanzapine portfolio. What's your understanding of gross margin and how it affects a company's profitability? | |
| Action: User Message | Details: What is the stock price | |
| Action: Response | Details: In our discussion, we've established that the stock price has been increasing over the past few months. Specifically, let's take a look at the 2023 monthly stock price for Eli Lilly: Jan: $339.14, Feb: $307.68, Mar: $339.52, Apr: $391.36, May: $425.68, Jun: $464.85, Jul: $450.55, Aug: $550.50, Sep: $533.55, Oct: $550.23, Nov: $588.18, Dec: $580.10. How do you think the | |
| Action: Show More of the Advisor’s Answer | Details: User continued the conversation | |
| Action: Response | Details: charming stock price pattern, particularly the recent increase in August and November, aligns with the company's strong financial performance and growth prospects we discussed? Would you like to know if the stock's beta, which measures its volatility relative to the market, is consistent with your risk tolerance? | |